Research on the distribution of TCM syndromes of autoimmune gastritis and its pathological correlation

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2300075454

Enrollment

Unknown

Registered

2023-09-05

Start date

2022-09-01

Completion date

Unknown

Last updated

2023-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autoimmune gastritis

Interventions

Patients with autoimmune gastritis: none

Eligibility

Sex/Gender

All

Age

18 Years to 79 Years

Inclusion criteria

Inclusion criteria: ? a.APCA or (and) IFA positive in serum; b.The pathology of gastric biopsy is consistent with gastric body/fundus mucosal atrophic lesions; c. The level of PG I decreased, PG I/PG II decreased, and G-17 increased. (Note: a is a prerequisite, b and c meet any of them). ?Age between 18-79 years old; ?The subjects gave informed consent to this study.

Exclusion criteria

Exclusion criteria: ? Patients with a history of gastric surgery; ? Patients with suspected malignant transformation (except gastric neuroendocrine tumor, NET) diagnosed by pathological diagnosis of gastric mucosa; ? Combined with serious primary diseases such as heart, brain, liver, kidney and hematopoietic system , or serious diseases that affect their survival; ? mentally ill patients

Design outcomes

Primary

Measure	Time frame
gastroscope;Biospy;Gastrin-17;Pepsinogen I;Pepsinogen II;	—

Countries

China

Contacts

Public ContactLiu Jing-Yu

Guang’anmen Hospital of China Academy of Chinese Medical Sciences

578945064@qq.com+86 186 7083 2322

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026